Analysis of Revenues
Paying user area
Try for free
Edwards Lifesciences Corp. pages available for free this week:
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Edwards Lifesciences Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Edwards Lifesciences Corp., income statement, revenues
US$ in thousands
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
- Overall Revenue Growth
- The total net sales demonstrate a consistent upward trend over the five-year period, increasing from $3,435,300 thousand in 2017 to $5,232,500 thousand in 2021. This represents a substantial increase in overall revenue, indicating positive business expansion.
- Transcatheter Aortic Valve Replacement (TAVR)
- This segment shows steady growth every year, starting from $2,023,800 thousand in 2017 and reaching $3,422,500 thousand in 2021. The growth is particularly notable in the last two years, suggesting increased market adoption or product demand associated with TAVR technology.
- Transcatheter Mitral and Tricuspid Therapies
- This category started at a very low base of $3,400 thousand in 2017 and experienced rapid growth to $86,000 thousand by 2021. The sharp increase, especially after 2018, indicates this may be a new or rapidly developing segment with significant expansion during the period.
- Surgical Structural Heart
- The Surgical Structural Heart segment exhibits some fluctuations. It decreased slightly from $807,100 thousand in 2017 to $761,600 thousand in 2018, then rose to $841,700 thousand in 2019, followed by another dip in 2020 to $761,800 thousand. By 2021, it increased again to $889,100 thousand. This pattern suggests market volatility or changing demand in this segment but with a positive recovery by the end of the period.
- Critical Care
- Critical Care revenues show steady but modest growth over the years, increasing from $601,000 thousand in 2017 to $834,900 thousand in 2021. The growth is fairly consistent with a minor decline from 2019 to 2020 but a rebound in 2021, pointing to stable demand in this segment.